When ischemic stroke patients do not receive intravelous alteplase to help dissolve clots, their odds of survival are significantly reduced, according to a study published in the American Journal of ...

Patients with minor acute ischemic strokes and deficits that are not clearly disabling at presentation do not derive a benefit from IV alteplase, according to results of the PRISMS trial, which was ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DALLAS -- Dual ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Among patients with acute ischemic stroke ...

Outcomes after stroke thrombectomy were not better with tissue plasminogen activator (tPA) withheld, according to the MR CLEAN-NO IV trial. Of more than 500 acute stroke patients with large vessel ...

Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...

Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers. Ischemic stroke patients who ...

Recent use of non-vitamin K antagonist oral anticoagulants (NOACs) is not associated with increased risk for bleeding following treatment with intravenous alteplase for ischemic stroke, new data ...

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...

A major international analysis of 2,313 patients, median age 71, found that giving an IV clot-busting drug before mechanical clot removal modestly increases brain-bleeding risk compared with ...

Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers at Georgia State University.